Apnimed priced an upsized IPO at $16 per share for gross proceeds of $192 million, with an over-allotment option that could add $24 million more, according to the company’s disclosed launch terms. The capital raise is positioned around a potential sleep-apnea drug launch early next year. The deal adds momentum to a busy IPO window where late-stage and near-launch biotechs seek public capital to fund pivotal studies and commercial readiness.